Document ID: chunk:federal_register_of_legislation:F2025C00201:reg:13762:p1
Version: federal_register_of_legislation:F2025C00201
Segment Type: reg
Provision Reference: reg 13762 (pt 1/3)
Character Range: 9539–13412

13762                                            Extracorporeal photopheresis for the treatment of chronic graft‑versus‑host disease, if:                                                                                                 1,908.35
                                                   (a) the person is:
                                                       (i) has received allogeneic haematopoietic stem cell transplantation; and
                                                       (ii) has been diagnosed with chronic graft versus host disease following the transplantation; and
                                                       (iii) steroid treatment is clinically unsuitable as the disease is steroid refractory or the person is steroid‑dependent or steroid‑intolerant; and
                                                   (b) the person has previously received an extracorporeal photopheresis treatment cycle and had a partial or complete response in at least one organ in response to treatment; and
                                                   (c) the person requires further extracorporeal photopheresis; and
                                                   (d) the service is delivered using an integrated, closed extracorporeal photopheresis system; and
                                                   (e) the service is provided in combination with the use of methoxsalen that is listed on the Pharmaceutical Benefits Scheme; and
                                                   (f) the service is provided by, or on behalf of, a specialist or consultant physician who:
                                                       (i) is practising in the speciality of haematology or oncology; and
                                                       (ii) has experience with allogeneic bone marrow transplantation.

                                                 Applicable once per treatment session (H)

Endnotes

Endnote 1—About the endnotes
The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history

Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes
The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change